Hope and Exploitation in Commercial Provision of Assisted Reproductive Technologies.

assisted reproductive technologies bioethics exploitation hope physician-patient relationship

Journal

The Hastings Center report
ISSN: 1552-146X
Titre abrégé: Hastings Cent Rep
Pays: United States
ID NLM: 0410447

Informations de publication

Date de publication:
Sep 2023
Historique:
medline: 16 11 2023
pubmed: 14 11 2023
entrez: 14 11 2023
Statut: ppublish

Résumé

Innovation is a key driver of care provision in assisted reproductive technologies (ART). ART providers offer a range of add-on interventions, aiming to augment standard in vitro fertilization protocols and improve the chances of a live birth. Particularly in the context of commercial provision, an ever-increasing array of add-ons are marketed to ART patients, even when evidence to support them is equivocal. A defining feature of ART is hope-hope that a cycle will lead to a baby or that another test or intervention will make a difference. Yet such hope also leaves ART patients vulnerable in a variety of ways. This article argues that previous attempts to safeguard ART patients have neglected how the use of add-ons in commercial ART can exploit patients' hopes. Commercial providers of ART should provide add-ons only free of charge, under a suitable research protocol.

Identifiants

pubmed: 37963135
doi: 10.1002/hast.1513
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

30-41

Subventions

Organisme : National Health and Medical Research Council of Australia
ID : APP1181401

Informations de copyright

© 2023 The Hastings Center.

Références

Reprod Biomed Online. 2020 Jan;40(1):2-5
pubmed: 31924494
Hum Reprod. 2017 Mar 1;32(3):485-491
pubmed: 28158511
Hum Reprod. 2021 Jun 18;36(7):1854-1861
pubmed: 33942073
Hastings Cent Rep. 2023 Sep;53(5):30-41
pubmed: 37963135
J Med Ethics. 2019 May;45(5):346-350
pubmed: 30745435
Reprod Biomed Online. 2019 Jun;38(6):853-856
pubmed: 31023611
BMJ. 2004 Jun 19;328(7454):1494-6
pubmed: 15205296
Hum Reprod Open. 2020 Dec 23;2020(4):hoaa059
pubmed: 33392395
Hum Fertil (Camb). 2013 Mar;16(1):22-5
pubmed: 23530725
BMJ Open. 2016 Nov 27;6(11):e013940
pubmed: 27890866
Int J Behav Med. 2022 Apr;29(2):209-219
pubmed: 34008158
Hastings Cent Rep. 2008 Sep-Oct;38(5):49-55
pubmed: 18947141
Fertil Steril. 2019 Dec;112(6):973-977
pubmed: 31703942
Bioethics. 2015 Sep;29(7):478-87
pubmed: 25425540
BMJ. 2016 Dec 1;355:i6434
pubmed: 27908888

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH